scholarly journals Features of ophthalmic disorders in patients with chronic viral hepatitis C before and after antiviral treatment

2012 ◽  
Vol 93 (6) ◽  
pp. 989-991
Author(s):  
G E Akberova ◽  
F R Saifullina ◽  
I M Khaertynova
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Color Vision ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Before And After ◽  
Chronic Viral Hepatitis C

Aim. To study the features of ophthalmic disorders in patients with chronic viral hepatitis C before and after antiviral treatment. Methods. 40 patients (80 eyes) with chronic hepatitis C were observed (the main group). The control group consisted of 20 healthy subjects (40 eyes). To diagnose chronic hepatitis C infection and to assess liver damage a set of clinical, epidemiological and laboratory tests was performed. All patients underwent liver ultrasonography. The diagnosis of chronic hepatitis C was set up according to presence of immunoglobulin M and G to hepatitis C virus and presence of viral RNA on polymerase chain reaction in peripheral blood. Along with standard opthalmic examination, visual field testing using the white and chromatic light and visual lability testing were performed. Results. Color vision impairments were diagnosed in 50% of patients with chronic hepatitis C, with decreased visual lability for the red and green colors in 100% of cases. After 6 months of antiviral treatment restoration of visual function was observed. The durability of visual impairments in patients with chronic hepatitis C depended on the severity of the disease. Conclusion. In patients with chronic hepatitis C with the short term of the disease ophthalmic disorders such as decreased peripheral vision, color vision impairments, decreased visual lability are reversible.

scholarly journals NEW PROGNOSTIC METHOD FOR ESTIMATION OF LIPID DISTRESS SYNDROME DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C

2019 ◽  
Vol 4 (1) ◽  
pp. 16-19
Author(s):  
Dmitrii Yu. Konstantinov ◽  
German V. Nedugov ◽  
Larisa L. Popova ◽  
Elena A. Konstantinova
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Distress Syndrome ◽  
Function Analysis ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

Objectives - to work out a prognostic method, based on clinical and laboratory data, which can predict the development of lipid distress syndrome in patients with chronic viral hepatitis C. Material and methods. We studied the outcomes of chronic viral hepatitis C with respect to development of lipid distress syndrome in 267 patients who did not receive antiviral therapy during the observation period lasting for 1 to 7 years. Results. Discriminant function analysis of the data acquired after examination of 167 patients helped us to work out a discriminative model of predicting the development of lipid distress syndrome in patients with chronic viral hepatitis C in the absence of antiviral therapy. Crosschecking of prediction accuracy was carried out on the data of examination of other 100 patients. Conclusion. The designed technique for predicting the development of lipid distress syndrome in patients with chronic hepatitis C is characterized by point estimates of sensitivity and prognostic value of the negative result equal to 100%.

scholarly journals NEW PERSPECTIVES OF PERSONALIZED THERAPY OF CHRONIC HEPATITIS C

2013 ◽  
Vol 18 (3) ◽  
pp. 27-36
Author(s):  
G. V. Sapronov ◽  
L. I. Nikolaeva
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Protease Inhibitors ◽  
Mechanism Of Action ◽  
Chronic Viral Hepatitis ◽  
Pharmacological Agents ◽  
Viral Hepatitis C ◽  
Molecular Mechanism Of Action ◽  
Chronic Viral Hepatitis C

The aim of this review - to analyze the possibilities of traditional therapy and opening new perspectives and approaches to personalized theraру of patients with chronic viral hepatitis C. There are considered the viral and patien tfactors that have an mpact on the efficacy of theтру with interferon-a2 and ribavirin. There are presented data on the molecular mechanism of action of these drugs preparations. There are considered new antiviral drugs (protease inhibitors) and pharmacological agents being under development and targeted to viral polymerase andprotein NS5A.

scholarly journals Current international guidelines for the management of patients with chronic viral hepatitis C

2020 ◽  
pp. 72-77
Author(s):  
Ju. L. Tonkikh ◽  
A. V. Vasyutin ◽  
V. V. Tsukanov
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Antiviral Treatment ◽  
Antiviral Drug ◽  
Chronic Viral Hepatitis ◽  
Response To Therapy ◽  
Risk Of Infection ◽  
Viral Hepatitis C ◽  
Increased Risk ◽  
Chronic Viral Hepatitis C

The new American Association for the Study of Liver Diseases and Infectious Diseases Society of America recommendations for the management of hepatitis C patients are analyzed. To screen for viral hepatitis C, it is recommended that antibodies to the hepatitis C virus and RNA be detected in individuals with increased risk of infection. Patients with an increased risk of infection include people who inject narcotic drugs; patients with prolonged hemodialysis; health workers after contact with the blood or mucous membranes of a patient with viral hepatitis C; persons who received blood transfusions or blood components before 1987. In most patients, non-invasive tests can be used to diagnose liver fibrosis, which include physical examination, determination of serum fibrosis markers, including the FIB-4 index, ultrasound or computed tomography of the liver and liver elastography. The introduction of direct antiviral drug regimens significantly facilitated the treatment of viral hepatitis C and significantly increased the frequency of response to antiviral treatment. The development of combined pathogenetic regimens with a relatively short duration of treatment has become an important step in the management of patients with viral hepatitis C. New American recommendations suggest the use of pangenotypic regimens in patients with viral hepatitis C without fibrosis or with compensated liver cirrhosis: glecaprevir (300 mg)/pibrentasvir (120 mg) 3 pills per day within 8 weeks or the combination of sofosbuvir (400 mg)/velpatasvir (100 mg) 1 pill per day for 12 weeks with the expected response to therapy in 95–100% of patients. Review authors note a number of rational aspects of the new American recommendations, but consider that experienced and qualified specialists should treat patients with chronic viral hepatitis C in Russia.

scholarly journals Significance of iron reduction for the therapy of chronic hepatitis C

2005 ◽  
Vol 62 (2) ◽  
pp. 161-164 ◽  
Author(s):  
Darko Nozic ◽  
Bela Balint ◽  
Nebojsa Stankovic ◽  
Jovan Dimitrijevic ◽  
Gorana Neskovic
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Iron Overload ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Iron Reduction ◽  
Elevated Serum ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Iron Deposits

Background. It has been established that many patients with chronic hepatitis C have elevated serum iron, feritin levels and iron deposits in the liver. Therefore, the liver damage due to hepatitis C virus may be aggravated with iron overload. In many studies higher levels of iron in the blood and the liver were connected with the decreased response to interferon-alfa therapy for chronic viral hepatitis C. Recent introduction of pegylated interferons plus ribavirin has improved the therapeutic response, so it is now possible to cure more than 50% of the patients. Case report. Three patients with chronic hepatitis C and iron overload were presented. Iron reduction therapy using phlebotomy or eritrocytapheresis with plasmapheresis was done at different times in regard to specific antiviral therapy or as a sole therapy. Conclusion. It has been shown that iron reduction, sole or combined with antiviral therapy, led to the deacreased aminotransferase serum activity and might have slow down the evolution of chronic hepatitis C viral infection.

scholarly journals Assessment of adherence to chronic viral hepatitis C treatment in Romania: an open, single center, prospective study

2016 ◽  
Vol 2 (2) ◽  
pp. 59-68
Author(s):  
Anca Streinu-Cercel ◽  
Maria-Magdalena Moțoi ◽  
Alina Cristina Neguț ◽  
Luminița Bradu ◽  
Daniela Manolache ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Prospective Study ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Single Center ◽  
Hepatitis C Treatment ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany

2018 ◽  
Vol 35 (4) ◽  
pp. 661-666 ◽  
Author(s):  
Cristina Stasi ◽  
Caterina Silvestri ◽  
Roberto Berni ◽  
Maurizia Rossana Brunetto ◽  
Anna Linda Zignego ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Clinical Data ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C
Sign in / Sign up

Export Citation Format

Share Document